Halms, Theresa
Gaigl, Gabriele
Lorenz, Carolin
Güler, Duygu
Khorikian-Ghazari, Naiiri
Röh, Astrid
Burschinski, Angelika
Gaebel, Wolfgang
Flick, Marisa
Pielenz, Charline
Salveridou-Hof, Eva
Schneider-Axmann, Thomas
Schneider, Marco
Wagner, Elias
Falkai, Peter
Lucae, Susanne
Rentrop, Michael
Zwanzger, Peter
Seemüller, Florian
Landgrebe, Michael
Ortner, Marion
Schneeweiß, Bertram
Brieger, Peter
Ajayi, Klemens
Schwarz, Michael
Heres, Stephan
Marstrander, Nicolay
Becker, Thomas
Jäger, Markus
Putzhammer, Albert
Frasch, Karel
Steber, Raimund
Leucht, Stefan
Hasan, Alkomiet
Funding for this research was provided by:
Gemeinsamer Bundesausschuss (01VSF20024)
German Center of Mental Health (01EE2303C)
Universitätsklinikum Augsburg
Article History
Received: 5 April 2024
Accepted: 17 July 2024
First Online: 29 July 2024
Declarations
:
: The project (incl. protocol) was approved by the local ethics committees of the University Hospital Munich (Ref. 21-0780). The survey was reviewed by the data protection officer of the University Hospital Munich.The participants provided their written informed consent to participate in this trial.
: Not applicable.
: A.H. was a member of advisory boards and received paid speakership by Boehringer-Ingelheim, Lundbeck, Otsuka, Rovi, and Recordati. He received paid speakership by AbbVie and Advanz. He is editor of the AWMF German guidelines for schizophrenia. M.R. was a member of advisory board and received paid speakership by Rovi. K.F. has received travel grants for congress participation by Janssen; he is vice chairman of ackpa (Association of Chief Psychiatrists in German General Hospitals) and Executive Committee Member of the DGPPN (German Association for Psychiatry, Psychotherapy and Psychosomatics). P.F. is co-editor of the German (DGPPN) schizophrenia treatment guidelines, co-author of the WFSBP schizophrenia treatment guidelines; on advisory boards and speaker fees from Janssen, Lundbeck, Otsuka, Servier, and Richter. In the last three years. S.L.2 has received honoraria for advising/consulting and/or for lectures and/or for educational material from Angelini, Boehringer Ingelheim, Eisai, Ekademia, GedeonRichter, Janssen, Karuna, Kynexis, Lundbeck, Medichem, Medscape, Mitsubishi, Neurotorium, Otsuka, NovoNordisk, Recordati, Rovi, Teva. Over the past three years, S.H. has received lecture fees from Johnson & Johnson, Boehringer-Ingelheim, Recordati and Otsuka/Lundbeck, as well as fees for scientific advisory boards in clinical trials for TEVA, ROVI, Merck and Boehringer-Ingelheim. All other authors do not report any conflicts of interest related to the subject of this work.